Interventions for managing antiretroviral therapy-associated lipoatrophy

Current Opinion in Infectious Diseases

Volumn 18, Issue 1, 2005, Pages 25-33

  Sutinen, Jussi ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Antiretroviral therapy; HIV; Lipoatrophy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; ANTIDIABETIC AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; EMTRICITABINE; FILLER; GLITAZONE DERIVATIVE; LAMIVUDINE; PIOGLITAZONE; ROSIGLITAZONE; STAVUDINE; TENOFOVIR; TROGLITAZONE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADIPOSE TISSUE; AUTOTRANSPLANTATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFECT; DRUG SUBSTITUTION; DUAL ENERGY X RAY ABSORPTIOMETRY; FACE DEFORMITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LIPOATROPHY; LIVER TOXICITY; PLASTIC SURGERY; REVIEW; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL; BIODEGRADABLE IMPLANT; CHEMICALLY INDUCED DISORDER; FACE; HIV ASSOCIATED LIPODYSTROPHY;

ABSORBABLE IMPLANTS; ADIPOSE TISSUE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FACE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; THIAZOLIDINEDIONES;

EID: 17544375309     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200502000-00005     Document Type: Review

References (68)

1. Koutnikova H, Auwerx J. Regulation of adipocyte differentiation. Ann Med 2001; 33:556-561.
2. Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 2000; 16:145-171.
3. Gougeon ML, Penicaud L, Fromenty B, et al. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antiviral Ther 2004; 9:161-177. A comprehensive and in-depth review on adipocyte biology and on the available in-vitro and in-vivo data on the potential mechanisms of antiretroviral-associated lipodystrophy.
4. Gregoire FM. Adipocyte differentiation: from fibroblast to endocrine cell. Exp Biol Med (Maywood) 2001; 226:997-1002.
5. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003; 14:137-145. A compact update on the paracrine/autocrine functions of adipose tissue regulating whole-body metabolism and insulin resistance.
6. Sutinen J, Korsheninnikova E, Funahashi T, et al. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab 2003; 88:1907-1910.
7. Linn AS, Richelsen B, Pedersen SB, et al. Increased expression of TNF-α, IL-6, and IL-8 in HIV-associated lipodystrophy. Implications for the reduced expression and plasma levels of adiponectin. Am J Physiol Endocrinol Metab 2003; 285:E1072-E1080. One of the first human studies to demonstrate altered gene expression in lipoatrophic adipose tissue.
8. Koutkia P, Grinspoon S. HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies. Annu Rev Med 2004; 55:303-317. A comprehensive and up-to-date review covering the pathogenesis, treatment and prognosis of HIV-associated lipodystrophy.
9. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-1031.
10. Kannisto K, Sutinen J, Korsheninnikova E, et al. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma coactivator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 2003; 17:1753-1762. The first human study directly to associate altered gene expression with lipodystrophy by comparing two groups of HIV-infected, HAART-treated patients, one with and the other without lipodystrophy.
11. Jan V, Cervera P, Maachi M, et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antiviral Ther 2004; 9: 555-564. A recent study to expand the list of genes, the expression of which are altered in lipodystrophy.
12. Nolan D, Hammond E, James I, et al. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antiviral Ther 2003; 8:617-626. A study demonstrating an association between the severity of mtDNA in adipocytes and the extent of fat loss with some longitudinal data.
13. Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 1999; 13: 2261-2267.
14. Hammond E, Nolan D, James I, et al. Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy. AIDS 2004; 18:815-817. A study demonstrating not only the depletion of mtDNA in adipocytes, but also a reduction in the expression and activity of enzymes coded by mtDNA.
15. Mallon P, Unemori P, Bowen M, et al. Nucleoside reverse transcriptase inhibitors decrease mitochondrial and PPARgamma gene expression in adipose tissue after only 2 weeks in HIV-uninfected healthy adults. In: 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, USA 2004 [abstract 76]. The first human study to demonstrate an acute effect of NRTIs on gene expression in adipocytes in vivo.
16. Caron M, Auclair M, Vigouroux C, et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50:1378-1388.
17. Lafaurie M, Dolivo M, Boulu D, et al. Treatment of facial lipoatrophy with injections of polylactic acid in HIV-infected patients: results from a cohort of 94 patients. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 8-11 February 2004 [Abstract 726].
18. Schwenk A. Methods of assessing body shape and composition in HIV-associated lipodystrophy. Curr Opin Infect Dis 2002; 15:9-16.
19. Zhang B, MacNaul K, Szalkowski D, et al. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab 1999; 84:4274-4277.
20. Wentworth JM, Burris TP, Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. J Endocrinol 2000; 164:R7-R10.
21. Lenhard JM, Furfine ES, Jain RG, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res 2000; 47:121-129.
22. Ben-Romano R, Rudich A, Torok D, et al. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS 2003; 17:23-32.
23. Rudich A, Vanounou S, Riesenberg K, et al. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes 2001; 50:1425-1431.
24. Ranganathan S, Kern PA. The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes. J Endocrinol 2002; 172:155-162.
25. Dowell P, Flexner C, Kwiterovich PO, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 2000; 275:41325-41332.
26. Mauss S, Corzillius M, Wolf E, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med 2002; 3:49-55.
27. Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002; 34:1396-1405.
28. Hansen BR, Haugaard SB, Iversen J, et al. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review. Scand J Infect Dis 2004; 36:244-253. An up-to-date and comprehensive review summarizing the available data on the effects of any modification of HAART on lipodystrophy and other metabolic complications.
29. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288:207-215.
30. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18:1029-1036. An extension of the MITOX study showing a continuous increase in fat mass for 104 weeks after switching stavudine (or zidovudine) to abacavir.
31. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-270.
32. Moyle GJ, Baldwin C, Langroudi B, et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003; 33:22-28.
33. John M, McKinnon EJ, James IR, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003; 33:29-33.
34. Noor M, Dezii C, McLaren C, et al. Baseline triglyceride levels predict development of lipoatrophy in patients treated with stavudine extended-release/prolonged-release capsules or stavudine immediate-release. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 8-11 February 2004 [abstract 722].
35. Boyd M, Bien D, Ruxrungtham K, et al. Lipodystrophy in patients switched to indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd after failing nucleoside combination therapy: 96 week lipodystrophy outcomes in HIV-NAT 009. In: Program and abstracts of the 15th International AIDS Conference. Bangkok, Thailand, 11-16 July 2004 [abstract WePeB5867].
36. Boyd M, Bien D, Srasuebkul P, et al. Lipodystrophy in patients switched to indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd after failing nucleoside combination therapy: a prospective, 48-week observational substudy of HIV-NAT 009. In: 10th Conference on Retroviruses and Opportunistic Infections. Boston, USA, 10-14 February 2003 [abstract 738].
37. 7 Hittinger G, Poggi C, Beyssac JM, et al. Lipodystrophy syndrome in HIV infected patients taking a NRTI combination, partial reversion with a one-week on/off treatment, oxygen assay, results at 48 weeks. In: Program and abstracts of the 15th International AIDS Conference. Bangkok, Thailand, 11-16 July 2004 [abstract WePeB5963].
38. Milinkovic A, Martinez E, Vidal S, et al. Impact of structured therapy interruption on body composition of chronically HIV-infected patients: preliminary 1-year results. Antiviral Ther 2003; 8:L61-L62.
39. Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA 2004; 292:180-189.
40. + ART-naive patients. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 8-11 February 2004. [abstract 717].
41. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
42. Miralles Alvarez C, Torres Perea R, Sanz Sanz J, et al. Identification and follow up of adverse events related to NRTI use that in the clinical practice causes its substitution for tenofovir DF (RECOVER Study). In: Program and Abstracts of the 15th International AIDS Conference. Bangkok, Thailand, 11-16 July 2004 [abstract WePeB5880].
43. Gale EA. Lessons from the glitazones: a story of drug development. Lancet 2001; 357:1870-1875.
44. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270:12953-12956.
45. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47:507-514.
46. Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 2001; 44:2210-2219.
47. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51:797-802.
48. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86:280-288.
49. Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24:1226-1232.
50. Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24:308-315.
51. Sutinen J, Häkkinen A-M, Westerbacka J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antiviral Ther 2003; 8:199-207. The first placebo-controlled trial to treat HAART-associated lipodystrophy with an insulin-sensitizing agent, rosiglitazone, demonstrating no effect on body composition and an unexpected increase in blood lipids. Insulin sensitivity and liver fat content improved.
52. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004; 363:429-438. A large placebo-controlled trial with rosiglitazone for 48 weeks demonstrating no effect on body composition in patients with HAART-associated lipodystrophy.
53. Hadigan C, Yawetz S, Thomas A, et al. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 2004; 140:786-794. A placebo-controlled trial showing some improvement in body composition with rosiglitazone after 3 months of treatment and an improvement in insulin sensitivity using the clamp technique.
54. Gelato MC, Mynarcik DC, Quick JL, et al. I. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 2002; 31:163-170.
55. Calmy A, Hirschel B, Hans D, et al. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. AIDS 2003; 17:770-772.
56. Walli R, Michl GM, Muhlbayer D, et al. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med Berl 2000; 199:253-262.
57. Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003; 17:2471-2477. The first clinical study on the use of polylactic acid in HAART-associated facial lipoatrophy.
58. Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004; 5: 82-87. The first comparative study to demonstrate an improvement in facial lipoatrophy with polylactic acid in those receiving immediate treatment when compared with untreated subjects (delayed treatment).
59. Boix V. Polylactic acid implants. A new smile for lipoatrophic faces? AIDS 2003; 17:2533-2535.
60. Andre P. Evaluation of the safety of a non-animal stabilized hyaluronic acid (NASHA - Q-Medical, Sweden) in European countries: a retrospective study from 1997 to 2001. J Eur Acad Dermatol Venereol 2004; 18:422-425.
61. Walther RA. Facial lipodystrophy in patients with HIV infections troublesome to treat [in Swedish]. Lakartidningen 2002; 99:3826-3829.
62. Ritt MJ, Hillebrand-Haverkort ME, ten Veen JH. Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy. Acta Chir Plast 2001; 43:54-56.
63. Protopapa C, Sito G, Caporale D, Cammarota N. Bio-Alcamid in drug-induced lipodystrophy. J Cosmet Laser Ther 2003; 5:226-230.
64. Formigli L, Zecchi S, Protopapa C, et al. Bio-Alcamid: an electron micro scopic study after skin implantation. Plast Reconstruct Surg 2004; 113:1104-1106.
65. Serra MS, Oyafuso LKM, Troppe BM. Polymethylmethacrylate (PMMA) for facial atrophy treatment: 5 years follow-up. In: Program and Abstracts of the 15th International AIDS Conference. Bangkok, Thailand, 11-16 July 2004 [abstract MoOrB1060].
66. Coleman SR. Facial recontouring with lipostructure. Clin Plast Surg 1997; 24:347-367.
67. Levan P, Nguyen TH, Lallemand F, et al. Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. AIDS 2002; 16:1985-1987.
68. Strauch B, Baum T, Robbins N. Treatment of human immunodeficiency virus-associated lipodystrophy with dermafat graft transfer to the malar area. Plast Reconstruct Surg 2004; 113:363-370.